DAX25.421 +0,1%Est506.030 +0,2%MSCI World4.343 -0,1%Top 10 Crypto12,45 +2,8%Nas23.650 -0,4%Bitcoin80.235 +2,7%Euro1,1655 -0,1%Öl65,63 +2,1%Gold4.592 -0,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 TKMS thyssenkrupp Marine Systems TKMS00 NVIDIA 918422 Novo Nordisk A3EU6F Bayer BAY001 Deutsche Telekom 555750 DroneShield A2DMAA RENK RENK73 Siemens Energy ENER6Y BioNTech (ADRs) A2PSR2 Infineon 623100 Lufthansa 823212 SAP 716460 Allianz 840400 Amazon 906866
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Nach US-Inflationsdaten: DAX schließt kaum verändert -- EZB-Ausblick: Zinserhöhung unwahrscheinlich -- AMD, Intel, Google, JPMorgan, Siemens Energy, BioNTech, Rüstungsaktien, DEUTZ, im Fokus
Top News
Meta Platforms-Aktie: Warum die Zusammenarbeit mit Google für NVIDIA zum Problem werden könnte Meta Platforms-Aktie: Warum die Zusammenarbeit mit Google für NVIDIA zum Problem werden könnte
Stellar: So viel Wert wäre mit einer Investition von vor 1 Jahr verloren gegangen Stellar: So viel Wert wäre mit einer Investition von vor 1 Jahr verloren gegangen
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
Verteidigung als Anlagechance: Mit diesem ETF erhältst du Zugang zu europäischen Unternehmen aus dem Luft-, Raumfahrt- und Verteidigungssektor

AbbVie Aktie

Kaufen
Verkaufen
AbbVie Aktien-Sparplan
188,20 EUR -0,40 EUR -0,21 %
STU
219,48 USD -0,57 USD -0,26 %
BTT
AbbVie jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.333,53 Mrd. EUR

KGV74,34Div. Rendite3,54%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1J84E

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS00287Y1091

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolABBV

AbbVie Aktien News

DatumMeistgelesen
PR NewswireAllergan Aesthetics to Present New Data at 2024 American Society for Dermatologic Surgery (ASDS) to Showcase Depth Across Facial Aesthetics and Insight into Patient Perception
PR NewswireAvailable Nationwide: JUVÉDERM® VOLUMA® XC for Moderate to Severe Temple Hollowing
PR NewswireAbbVie to Host Third-Quarter 2024 Earnings Conference Call
PR NewswireAbbVie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer
PR NewswireAbbVie and SpinUp Foster Canadian Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award
PR NewswireAbbVie and SpinUp Foster Canadian Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award
PR NewswireAbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
PR NewswireNew Analysis Demonstrates the Efficacy of RINVOQ® (upadacitinib) in Atopic Dermatitis with Varying Degrees of Severity in Head and Neck Involvement
PR NewswireAbbVie Receives Positive CHMP Opinion for Mirvetuximab Soravtansine (ELAHERE®) for the Treatment of Certain Adult Ovarian Cancer
PR NewswireAllergan Aesthetics Launches BOTOX® Cosmetic (onabotulinumtoxinA) for Masseter Muscle Prominence (MMP) in Adults in China
PR NewswireAbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in Tumor Types with High Unmet Needs
PR NewswireAbbVie Declares Quarterly Dividend
PR NewswireAbbVie's VRAYLAR® (cariprazine) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for the Treatment of Schizophrenia
PR NewswireAbbVie Awards Scholarships to 45 U.S. Students Living With Chronic Immune-Mediated Diseases
PR NewswireSkinMedica® Revolutionizes Skin Hydration with the Introduction of HA5® Hydra Collagen Replenish + Restore Hydrator
PR NewswireEuropean Commission Grants Second Indication Approval for TEPKINLY® (epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
PR NewswireAbbVie Announces Ontario and Quebec are First Provinces to Reimburse Subcutaneous EPKINLY™ (epcoritamab) for the Treatment of Diffuse Large B-Cell Lymphoma Under New Early Access Process
PR NewswireAbbVie Announces Ontario and Quebec are First Provinces to Reimburse Subcutaneous EPKINLY™ (epcoritamab) for the Treatment of Diffuse Large B-Cell Lymphoma Under New Early Access Process
PR NewswireAbbVie Completes Acquisition of Cerevel Therapeutics
PR NewswireAllergan Aesthetics Celebrates the Second Annual JUVÉDERM® Day
PR NewswireAbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
PR NewswireAbbVie's EPKINLY™ Receives First-Ever Time-Limited Reimbursement Recommendation by Canada's Drug Agency
PR NewswireAbbVie's EPKINLY™ Receives First-Ever Time-Limited Reimbursement Recommendation by Canada's Drug Agency
PR NewswireAbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Giant Cell Arteritis
PR NewswireAbbVie Announces Appointment of Roopal Thakkar, M.D. as Executive Vice President, Research & Development and Chief Scientific Officer
PR NewswireAbbVie to Host Second-Quarter 2024 Earnings Conference Call
PR NewswireRobert A. Michael Assumes Role as AbbVie Chief Executive Officer
PR NewswireAbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
PR NewswireAbbVie Acquires Celsius Therapeutics
PR NewswireIntroducing Allē Payment Plans, Powered by Cherry
PR NewswireU.S. Food and Drug Administration Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma
PR NewswireAbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)
PR NewswireAbbVie Declares Quarterly Dividend
PR NewswireAbbVie Appoints Roxanne S. Austin as Lead Independent Director of the Board of Directors
PR NewswireU.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease
PR NewswireAbbVie Recommends Shareholders Reject Tutanota's "Mini-Tender" Offer
PR NewswireAbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease
PR NewswireAbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRα) Expressing Platinum-Sensitive Ovarian Cancer
PR NewswireSkinMedica® Celebrates 25 Years of Empowering Radiant Skin
PR NewswireAbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their Careers

AbbVie News

AbbVie News: auf dieser Seite finden Sie alle AbbVie News und Nachrichten zur AbbVie Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch AbbVie News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um AbbVie News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.